BOCEPREVIR (BioDeep_00000789093)
代谢物信息卡片
BOCEPREVIR
化学式: C27H45N5O5 (519.342052)
中文名称: 波普瑞韦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C
InChI: InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
描述信息
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AP - Antivirals for treatment of hcv infections
C254 - Anti-Infective Agent > C281 - Antiviral Agent
COVID info from Guide to PHARMACOLOGY
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:68621
- KEGGdrug: D08876
- PubChem: 10324367
- DrugBank: DB08873
- ChEMBL: CHEMBL218394
- CAS: 394730-60-0
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Matthias Göhl, Linlin Zhang, Haifa El Kilani, Xinyuanyuan Sun, Kaixuan Zhang, Mark Brönstrup, Rolf Hilgenfeld. From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.
Molecules (Basel, Switzerland).
2022 Jul; 27(13):. doi:
10.3390/molecules27134292. [PMID: 35807537] - Emily G Hicks, Sylvie E Kandel, Jed N Lampe. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (Mpro) inhibitors.
Bioorganic & medicinal chemistry letters.
2022 06; 66(?):128732. doi:
10.1016/j.bmcl.2022.128732. [PMID: 35427739] - Daniel W Kneller, Hui Li, Gwyndalyn Phillips, Kevin L Weiss, Qiu Zhang, Mark A Arnould, Colleen B Jonsson, Surekha Surendranathan, Jyothi Parvathareddy, Matthew P Blakeley, Leighton Coates, John M Louis, Peter V Bonnesen, Andrey Kovalevsky. Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.
Nature communications.
2022 04; 13(1):2268. doi:
10.1038/s41467-022-29915-z. [PMID: 35477935] - Yining Wang, Pengfei Li, Marla Lavrijsen, Yang Li, Zhongren Ma, Maikel P Peppelenbosch, Mirza S Baig, Qiuwei Pan. Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions.
Archives of virology.
2022 Apr; 167(4):1125-1130. doi:
10.1007/s00705-022-05369-y. [PMID: 35171357] - Naoya Kitamura, Michael Dominic Sacco, Chunlong Ma, Yanmei Hu, Julia Alma Townsend, Xiangzhi Meng, Fushun Zhang, Xiujun Zhang, Mandy Ba, Tommy Szeto, Adis Kukuljac, Michael Thomas Marty, David Schultz, Sara Cherry, Yan Xiang, Yu Chen, Jun Wang. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.
Journal of medicinal chemistry.
2022 02; 65(4):2848-2865. doi:
10.1021/acs.jmedchem.1c00509. [PMID: 33891389] - Aditya K Padhi, Timir Tripathi. Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation.
Biochemical and biophysical research communications.
2021 05; 555(?):147-153. doi:
10.1016/j.bbrc.2021.03.118. [PMID: 33813274] - Jingxin Qiao, Yue-Shan Li, Rui Zeng, Feng-Liang Liu, Rong-Hua Luo, Chong Huang, Yi-Fei Wang, Jie Zhang, Baoxue Quan, Chenjian Shen, Xin Mao, Xinlei Liu, Weining Sun, Wei Yang, Xincheng Ni, Kai Wang, Ling Xu, Zi-Lei Duan, Qing-Cui Zou, Hai-Lin Zhang, Wang Qu, Yang-Hao-Peng Long, Ming-Hua Li, Rui-Cheng Yang, Xiaolong Liu, Jing You, Yangli Zhou, Rui Yao, Wen-Pei Li, Jing-Ming Liu, Pei Chen, Yang Liu, Gui-Feng Lin, Xin Yang, Jun Zou, Linli Li, Yiguo Hu, Guang-Wen Lu, Wei-Min Li, Yu-Quan Wei, Yong-Tang Zheng, Jian Lei, Shengyong Yang. SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model.
Science (New York, N.Y.).
2021 03; 371(6536):1374-1378. doi:
10.1126/science.abf1611. [PMID: 33602867] - Mohammad Hassan Baig, Tanuj Sharma, Irfan Ahmad, Mohammed Abohashrh, Mohammad Mahtab Alam, Jae-June Dong. Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study.
Molecules (Basel, Switzerland).
2021 Mar; 26(6):. doi:
10.3390/molecules26061678. [PMID: 33802860] - Yanmei Hu, Chunlong Ma, Tommy Szeto, Brett Hurst, Bart Tarbet, Jun Wang. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
ACS infectious diseases.
2021 03; 7(3):586-597. doi:
10.1021/acsinfecdis.0c00761. [PMID: 33645977] - Mohammad M Ghahremanpour, Julian Tirado-Rives, Maya Deshmukh, Joseph A Ippolito, Chun-Hui Zhang, Israel Cabeza de Vaca, Maria-Elena Liosi, Karen S Anderson, William L Jorgensen. Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
ACS medicinal chemistry letters.
2020 Dec; 11(12):2526-2533. doi:
10.1021/acsmedchemlett.0c00521. [PMID: 33324471] - Ognjen Perišić. Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues.
Biomolecules.
2020 09; 10(9):. doi:
10.3390/biom10091346. [PMID: 32967116] - Lifeng Fu, Fei Ye, Yong Feng, Feng Yu, Qisheng Wang, Yan Wu, Cheng Zhao, Huan Sun, Baoying Huang, Peihua Niu, Hao Song, Yi Shi, Xuebing Li, Wenjie Tan, Jianxun Qi, George Fu Gao. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
Nature communications.
2020 09; 11(1):4417. doi:
10.1038/s41467-020-18233-x. [PMID: 32887884] - Chunlong Ma, Michael Dominic Sacco, Brett Hurst, Julia Alma Townsend, Yanmei Hu, Tommy Szeto, Xiujun Zhang, Bart Tarbet, Michael Thomas Marty, Yu Chen, Jun Wang. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
Cell research.
2020 08; 30(8):678-692. doi:
10.1038/s41422-020-0356-z. [PMID: 32541865] - Meng-Hsuan Hsieh, Ming-Lun Yeh, Tung-Hung Su, Ta-Wei Liu, Chuang-Feng Huang, Ching-I Huang, Shu-Chi Wang, Jee-Fu Huang, Chia-Yen Dai, Jia-Horng Kao, Wan-Long Chuang, Pei-Jer Chen, Chun-Jen Liu, Ming-Lung Yu. Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan.
Journal of the Formosan Medical Association = Taiwan yi zhi.
2018 Jun; 117(6):497-504. doi:
10.1016/j.jfma.2017.06.007. [PMID: 28694000] - Midori Kjellin, Terése Wesslén, Erik Löfblad, Johan Lennerstrand, Anders Lannergård. The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort.
Upsala journal of medical sciences.
2018 Mar; 123(1):50-56. doi:
10.1080/03009734.2018.1441928. [PMID: 29536805] - R Maan, S H Al Marzooqi, J S Klair, J Karkada, O Cerocchi, M Kowgier, S M Harrell, K D Rhodes, H L A Janssen, J J Feld, A Duarte-Rojo. The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.
Alimentary pharmacology & therapeutics.
2017 07; 46(1):46-55. doi:
10.1111/apt.14117. [PMID: 28470850] - Lotte G van Vlerken, Faydra I Lieveld, Suzanne van Meer, Ger H Koek, Karin M J van Nieuwkerk, Pieter Friederich, Joop E Arends, Peter D Siersema, David M Burger, Karel J van Erpecum. Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring.
Clinics and research in hepatology and gastroenterology.
2016 Nov; 40(5):622-630. doi:
10.1016/j.clinre.2015.12.014. [PMID: 26867863] - Adeel A Butt, Peng Yan, Obaid S Shaikh, Raymond T Chung, Kenneth E Sherman. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
Liver international : official journal of the International Association for the Study of the Liver.
2016 09; 36(9):1275-83. doi:
10.1111/liv.13103. [PMID: 26928927] - Tim Zimmermann, Dietrich Hueppe, Stefan Mauss, Peter Buggisch, Heike Pfeiffer-Vornkahl, Daniel Grimm, Peter R Galle, Ulrich Alshuth. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
Journal of gastrointestinal and liver diseases : JGLD.
2016 Mar; 25(1):15-24. doi:
10.15403/jgld.2014.1121.251.a2a. [PMID: 27014750] - Sebastiaan J Hullegie, Brenda C M de Winter, Dirk Posthouwer, Peter P Koopmans, Mark A A Claassen, David M Burger, Bart J A Rijnders. Safety of rilpivirine and boceprevir coadministration in HIV-infected patients treated for acute hepatitis C virus infection.
AIDS (London, England).
2016 Jan; 30(3):529-30. doi:
10.1097/qad.0000000000000950. [PMID: 26558734] - Min Yao, Xin Lu, Yingfeng Lei, Jing Yang, Haiwei Zhao, Qinghua Qiao, Peijun Han, Zhikai Xu, Wen Yin. Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A Protease Activity.
PloS one.
2016; 11(3):e0150894. doi:
10.1371/journal.pone.0150894. [PMID: 26943641] - Amedeo De Nicolò, Adnan Mohamed Abdi, Lucio Boglione, Lorena Baiett, Sarah Allegra, Giovanni Di Perri, Antonio D'Avolio. UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells.
Journal of pharmaceutical and biomedical analysis.
2015 Nov; 115(?):443-9. doi:
10.1016/j.jpba.2015.08.004. [PMID: 26291788] - Noémie Calland, Marie-Emmanuelle Sahuc, Sandrine Belouzard, Véronique Pène, Pierre Bonnafous, Ahmed Atef Mesalam, Gaspard Deloison, Véronique Descamps, Sevser Sahpaz, Czeslaw Wychowski, Olivier Lambert, Priscille Brodin, Gilles Duverlie, Philip Meuleman, Arielle R Rosenberg, Jean Dubuisson, Yves Rouillé, Karin Séron. Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.
Journal of virology.
2015 Oct; 89(19):10053-63. doi:
10.1128/jvi.01473-15. [PMID: 26202241] - J E Arends, J T M van der Meer, D Posthouwer, W Kortmann, K Brinkman, S van Assen, C Smit, M van der Valk, M van der Ende, J Schinkel, P Reiss, C Richter, A I M Hoepelman. Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients.
The Netherlands journal of medicine.
2015 Aug; 73(7):324-30. doi:
NULL. [PMID: 26314715] - Philippe Sultanik, Vincent Mallet, Sylvie Lagaye, Armanda Casrouge, Céline Dorival, Yoann Barthe, Hélène Fontaine, Christophe Hézode, Estelle Mottez, Jean-Pierre Bronowicki, Fabrice Carrat, Ioannis Theodorou, Laurent Abel, Etienne Gayat, Arnaud Fontanet, Stanislas Pol, Matthew L Albert. Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
Liver international : official journal of the International Association for the Study of the Liver.
2015 Jul; 35(7):1833-44. doi:
10.1111/liv.12759. [PMID: 25556540] - Jessica Cusato, Sarah Allegra, Amedeo De Nicolò, Lucio Boglione, Giovanna Fatiguso, Adnan Mohamed Abdi, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio. Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics.
International journal of antimicrobial agents.
2015 Jun; 45(6):657-61. doi:
10.1016/j.ijantimicag.2015.01.019. [PMID: 25836019] - Sauzanne Khalilieh, Hwa-Ping Feng, Ellen G J Hulskotte, Larissa A Wenning, Joan R Butterton. Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug-drug interactions.
Clinical pharmacokinetics.
2015 Jun; 54(6):599-614. doi:
10.1007/s40262-015-0260-8. [PMID: 25787025] - Sandra Bodeau, Eric Nguyen-Khac, Caroline Solas, Youssef Bennis, Dominique Capron, Gilles Duverlie, Etienne Brochot. Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations.
Journal of clinical pharmacology.
2015 May; 55(5):517-24. doi:
10.1002/jcph.454. [PMID: 25535910] - Kristen T Hedrick, Shannon M Just, Daniel R Kahn. Probable boceprevir-induced hyponatremia in a patient with chronic hepatitis C.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2015 Mar; 72(6):449-52. doi:
10.2146/ajhp140025. [PMID: 25736938] - N L Latt, F Araz, N Alachkar, C M Durand, A Gurakar. Management of hepatitis C infection among patients with renal failure.
Minerva gastroenterologica e dietologica.
2015 Mar; 61(1):39-49. doi:
NULL. [PMID: 25390288] - Ellen G J Hulskotte, R Douglas Bruce, Hwa-Ping Feng, Lynn R Webster, Feng Xuan, Wen H Lin, Edward O'Mara, John A Wagner, Joan R Butterton. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy.
European journal of clinical pharmacology.
2015 Mar; 71(3):303-11. doi:
10.1007/s00228-014-1789-4. [PMID: 25666027] - L Boglione, A De Nicolò, C S Cardellino, T Ruggiero, V Ghisetti, G Cariti, G Di Perri, A D'Avolio. Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
2015 Feb; 21(2):205.e1-3. doi:
10.1016/j.cmi.2014.07.009. [PMID: 25658567] - Dorota Kozielewicz, Dorota Dybowska, Kornelia Karwowska, Magdalena Wietlicka-Piszcz. Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors.
Expert opinion on drug safety.
2015; 14(12):1815-25. doi:
10.1517/14740338.2015.1102882. [PMID: 26513231] - Véronique Loustaud-Ratti, Annick Rousseau, Paul Carrier, Chanlina Vong, Tristan Chambaraud, Jérémie Jacques, Marilyne Debette-Gratien, Denis Sautereau, Marie Essig. eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?.
Liver international : official journal of the International Association for the Study of the Liver.
2015 Jan; 35(1):71-8. doi:
10.1111/liv.12631. [PMID: 25039814] - Borja Mora-Peris, Laura Else, David Goldmeier, Alison Mears, Rosy Weston, Graham Cooke, Saye Khoo, David Back, Alan Winston. A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers.
The Journal of antimicrobial chemotherapy.
2015; 70(6):1812-5. doi:
10.1093/jac/dkv035. [PMID: 25693997] - Sarah Aherfi, Caroline Solas, Anne Motte, Jacques Moreau, Patrick Borentain, Saadia Mokhtari, Danielle Botta-Fridlund, Catherine Dhiver, Isabelle Portal, Jean-Marie Ruiz, Isabelle Ravaux, Sylvie Bregigeon, Isabelle Poizot-Martin, Andreas Stein, René Gérolami, Philippe Brouqui, Catherine Tamalet, Philippe Colson. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Journal of medical virology.
2014 Nov; 86(11):1868-76. doi:
10.1002/jmv.24016. [PMID: 25052594] - Mary Beth Wire, Lei Fang, Azra Hussaini, Joseph F Kleha, Dickens Theodore. Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Antimicrobial agents and chemotherapy.
2014 Nov; 58(11):6704-9. doi:
10.1128/aac.03091-14. [PMID: 25155600] - Mark Johnson, Julie Borland, Shuguang Chen, Paul Savina, Brian Wynne, Stephen Piscitelli. Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir.
British journal of clinical pharmacology.
2014 Nov; 78(5):1043-9. doi:
10.1111/bcp.12428. [PMID: 24838177] - Wen H Lin, Hwa-Ping Feng, Craig R Shadle, Terry O'Reilly, John A Wagner, Joan R Butterton. Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone.
European journal of clinical pharmacology.
2014 Sep; 70(9):1107-13. doi:
10.1007/s00228-014-1711-0. [PMID: 24992979] - Lionel Rostaing, Laurent Alric, Jacques Izopet, Nassim Kamar. What are the management issues for hepatitis C in dialysis patients?: hepatitis C virus infection and its treatment in patients with end-stage renal disease.
Seminars in dialysis.
2014 Sep; 27(5):451-5. doi:
10.1111/sdi.12290. [PMID: 25204878] - Akil Jackson, Antonio D'Avolio, Graeme Moyle, Stefano Bonora, Giovanni Di Perri, Laura Else, Marco Simiele, Gurmit Jagjit Singh, David Back, Marta Boffito. Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers.
The Journal of antimicrobial chemotherapy.
2014 Jul; 69(7):1911-5. doi:
10.1093/jac/dku060. [PMID: 24610312] - Christophe Hézode, Helene Fontaine, Celine Dorival, Fabien Zoulim, Dominique Larrey, Valerie Canva, Victor De Ledinghen, Thierry Poynard, Didier Samuel, Marc Bourliere, Laurent Alric, Jean-Jacques Raabe, Jean-Pierre Zarski, Patrick Marcellin, Ghassan Riachi, Pierre-Henri Bernard, Veronique Loustaud-Ratti, Olivier Chazouilleres, Armand Abergel, Dominique Guyader, Sophie Metivier, Albert Tran, Vincent Di Martino, Xavier Causse, Thong Dao, Damien Lucidarme, Isabelle Portal, Patrice Cacoub, Jerome Gournay, Veronique Grando-Lemaire, Patrick Hillon, Pierre Attali, Thierry Fontanges, Isabelle Rosa, Ventzislava Petrov-Sanchez, Yoann Barthe, Jean-Michel Pawlotsky, Stanislas Pol, Fabrice Carrat, Jean-Pierre Bronowicki. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Gastroenterology.
2014 Jul; 147(1):132-142.e4. doi:
10.1053/j.gastro.2014.03.051. [PMID: 24704719] - Manoli Vourvahis, Anna Plotka, Constantino Kantaridis, Annie Fang, Jayvant Heera. The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers.
Journal of acquired immune deficiency syndromes (1999).
2014 Apr; 65(5):564-70. doi:
10.1097/qai.0000000000000090. [PMID: 24346637] - Alex Thompson, Scott Devine, Mike Kattan, Andrew Muir. Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin.
PloS one.
2014; 9(8):e103370. doi:
10.1371/journal.pone.0103370. [PMID: 25084272] - Stefan Mauss, Dietrich Hueppe, Ulrich Alshuth. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir.
Hepatology (Baltimore, Md.).
2014 Jan; 59(1):46-8. doi:
10.1002/hep.26602. [PMID: 23813604] - V Virlogeux, P Pradat, F Bailly, G Funingana, F Gonçalves, M Maynard, K Hartig-Lavie, M Amiri, F Zoulim. Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.
Journal of viral hepatitis.
2014; 21(9):e98-e107. doi:
10.1111/jvh.12237. [PMID: 24612466] - Johanna Knapstein, Peter R Galle, Tim Zimmermann. Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
2014 Jan; 46(1):88-9. doi:
10.1016/j.dld.2013.08.133. [PMID: 24054768] - Zoubir Djerada, Catherine Feliu, Claire Tournois, Damien Vautier, Laurent Binet, Arnaud Robinet, Hélène Marty, Claire Gozalo, Denis Lamiable, Hervé Millart. Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology.
Journal of pharmaceutical and biomedical analysis.
2013 Dec; 86(?):100-11. doi:
10.1016/j.jpba.2013.08.002. [PMID: 23995753] - Christophe Hézode. Management of anaemia and other treatment complications.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
2013 Sep; 45 Suppl 5(?):S337-42. doi:
10.1016/j.dld.2013.07.010. [PMID: 24091113] - Gururaj Kalkeri, Chao Lin, Jenna Gopilan, Kevin Sloan, Rene Rijnbrand, Ann D Kwong. Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations.
Antimicrobial agents and chemotherapy.
2013 Sep; 57(9):4417-26. doi:
10.1128/aac.00399-13. [PMID: 23836176] - Manel Aouri, Darius Moradpour, Matthias Cavassini, Thomas Mercier, Thierry Buclin, Chantal Csajka, Amalio Telenti, Andri Rauch, Laurent A Decosterd. Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.
Antimicrobial agents and chemotherapy.
2013 Jul; 57(7):3147-58. doi:
10.1128/aac.00281-13. [PMID: 23629707] - Mark Sulkowski, Stanislas Pol, Josep Mallolas, Hugo Fainboim, Curtis Cooper, Jihad Slim, Antonio Rivero, Carmen Mak, Seth Thompson, Anita Y M Howe, Larissa Wenning, Peter Sklar, Janice Wahl, Wayne Greaves. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
The Lancet. Infectious diseases.
2013 Jul; 13(7):597-605. doi:
10.1016/s1473-3099(13)70149-x. [PMID: 23768747] - Clara T M M de Kanter, Angela P H Colbers, Maren I Blonk, Corrien P W G M Verweij-van Wissen, Bas J J W Schouwenberg, Joost P H Drenth, David M Burger. Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole.
The Journal of antimicrobial chemotherapy.
2013 Jun; 68(6):1415-22. doi:
10.1093/jac/dkt032. [PMID: 23429642] - E G J Hulskotte, H-P Feng, F Xuan, S Gupta, M G J A van Zutven, E O'Mara, J A Wagner, J R Butterton. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.
Antimicrobial agents and chemotherapy.
2013 Jun; 57(6):2582-8. doi:
10.1128/aac.02347-12. [PMID: 23529734] - Antonio D'Avolio, Amedeo De Nicolò, Danilo Agnesod, Marco Simiele, Adnan Mohamed Abdi, Sujan Dilly Penchala, Lucio Boglione, Giuseppe Cariti, Giovanni Di Perri. A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir.
Journal of pharmaceutical and biomedical analysis.
2013 May; 78-79(?):217-23. doi:
10.1016/j.jpba.2013.02.025. [PMID: 23501442] - Xiaoyan Chu, Xiaoxin Cai, Donghui Cui, Cuyue Tang, Anima Ghosal, Grace Chan, Mitchell D Green, Yuhsin Kuo, Yuexia Liang, Cheri M Maciolek, Jairam Palamanda, Raymond Evers, Thomayant Prueksaritanont. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Drug metabolism and disposition: the biological fate of chemicals.
2013 Mar; 41(3):668-81. doi:
10.1124/dmd.112.049668. [PMID: 23293300] - Robert A Ogert, John A Howe, John M Vierling, Paul Y Kwo, Eric J Lawitz, Jonathan McCone, Eugene R Schiff, David Pound, Mitchell N Davis, Stuart C Gordon, Natarajan Ravendhran, Lorenzo Rossaro, Ira M Jacobson, Robert Ralston, Eirum Chaudhri, Ping Qiu, Lisa D Pedicone, Clifford A Brass, Janice K Albrecht, Richard J O Barnard, Daria J Hazuda, Anita Y M Howe. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.
Antiviral therapy.
2013; 18(3):387-97. doi:
10.3851/imp2549. [PMID: 23406826] - Kyle P Hammond, Pamela Wolfe, James R Burton, Julie A Predhomme, Christine M Ellis, Michelle L Ray, Lane R Bushman, Jennifer J Kiser. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers.
Journal of acquired immune deficiency syndromes (1999).
2013 Jan; 62(1):67-73. doi:
10.1097/qai.0b013e318275da93. [PMID: 23075915] - Clara T M M de Kanter, Maren I Blonk, Angela P H Colbers, Bas J J W Schouwenberg, David M Burger. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2013 Jan; 56(2):300-6. doi:
10.1093/cid/cis824. [PMID: 23001704] - Karly P Garnock-Jones. Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.
Drugs.
2012 Dec; 72(18):2431-56. doi:
10.2165/11209560-000000000-00000. [PMID: 23231027] - Tarik Asselah. Interferon stimulated genes and hepatitis C virus infection.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
2012 Dec; 32(12):557-62. doi:
10.1089/jir.2012.0059. [PMID: 23151203] - Ellen Hulskotte, Samir Gupta, Fengjuan Xuan, Marga van Zutven, Edward O'Mara, Hwa-Ping Feng, John Wagner, Joan Butterton. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
Hepatology (Baltimore, Md.).
2012 Nov; 56(5):1622-30. doi:
10.1002/hep.25831. [PMID: 22576324] - C Moreno, P Deltenre. [Management of chronic hepatitis C in 2012 in Belgium].
Revue medicale de Bruxelles.
2012 Sep; 33(4):223-7. doi:
NULL. [PMID: 23091925] - Michelle Treitel, Thomas Marbury, Richard A Preston, Ilias Triantafyllou, William Feely, Edward O'Mara, Claudia Kasserra, Samir Gupta, Eric A Hughes. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Clinical pharmacokinetics.
2012 Sep; 51(9):619-28. doi:
10.1007/bf03261935. [PMID: 22799589] - Kay Seden, David Back. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
Current opinion in HIV and AIDS.
2011 Nov; 6(6):514-26. doi:
10.1097/coh.0b013e32834b54dc. [PMID: 22001895] - Marc G Ghany, David R Nelson, Doris B Strader, David L Thomas, Leonard B Seeff. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.
Hepatology (Baltimore, Md.).
2011 Oct; 54(4):1433-44. doi:
10.1002/hep.24641. [PMID: 21898493] - H Mo, C Yang, K Wang, Y Wang, M Huang, B Murray, X Qi, S-C Sun, M Deshpande, G Rhodes, M D Miller. Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.
Journal of viral hepatitis.
2011 May; 18(5):338-48. doi:
10.1111/j.1365-2893.2010.01314.x. [PMID: 20456634] - Peter W White, Montse Llinàs-Brunet, Ma'an Amad, Richard C Bethell, Gordon Bolger, Michael G Cordingley, Jianmin Duan, Michel Garneau, Lisette Lagacé, Diane Thibeault, George Kukolj. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
Antimicrobial agents and chemotherapy.
2010 Nov; 54(11):4611-8. doi:
10.1128/aac.00787-10. [PMID: 20823284] - Francisco Velázquez, Mousumi Sannigrahi, Frank Bennett, Raymond G Lovey, Ashok Arasappan, Stéphane Bogen, Latha Nair, Srikanth Venkatraman, Melissa Blackman, Siska Hendrata, Yuhua Huang, Regina Huelgas, Patrick Pinto, Kuo-Chi Cheng, Xiao Tong, Andrew T McPhail, F George Njoroge. Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.
Journal of medicinal chemistry.
2010 Apr; 53(8):3075-85. doi:
10.1021/jm9016027. [PMID: 20302300] - Peter A Warn, Andrew Sharp, Graham Morrissey, David W Denning. Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus.
International journal of antimicrobial agents.
2010 Feb; 35(2):146-51. doi:
10.1016/j.ijantimicag.2009.09.029. [PMID: 20015618] - Nigel J Liverton, Steven S Carroll, Jillian Dimuzio, Christine Fandozzi, Donald J Graham, Daria Hazuda, M Katherine Holloway, Steven W Ludmerer, John A McCauley, Charles J McIntyre, David B Olsen, Michael T Rudd, Mark Stahlhut, Joseph P Vacca. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
Antimicrobial agents and chemotherapy.
2010 Jan; 54(1):305-11. doi:
10.1128/aac.00677-09. [PMID: 19841155] - Harald Farnik, Juliane El-Duweik, Christoph Welsch, Christoph Sarrazin, Jörn Lötsch, Stefan Zeuzem, Gerd Geisslinger, Helmut Schmidt. Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2009 Dec; 877(31):4001-6. doi:
10.1016/j.jchromb.2009.10.013. [PMID: 19864192] - Ganfeng Wang, Yunsheng Hsieh, Kuo-Chi Cheng, Richard A Morrison, Srikanth Venkatraman, F George Njoroge, Larry Heimark, Walter A Korfmacher. Ultra-performance liquid chromatography/tandem mass spectrometric determination of diastereomers of SCH 503034 in monkey plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2007 Jun; 852(1-2):92-100. doi:
10.1016/j.jchromb.2006.12.038. [PMID: 17240204] - Dale J Kempf, Cheri Klein, Hui-Ju Chen, Larry L Klein, Clinton Yeung, John T Randolph, Yau Y Lau, Linda E Chovan, Zhiwen Guan, Lisa Hernandez, Teresa M Turner, Peter J Dandliker, Kennan C Marsh. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir.
Antiviral chemistry & chemotherapy.
2007; 18(3):163-7. doi:
10.1177/095632020701800306. [PMID: 17626600]